Previous
Previous

ARS Pharmaceuticals closes merger with Silverback Therapeutics and currently has over $280M in cash

Next
Next

ARS Pharmaceuticals announces FDA acceptance of NDA for neffy® (epinephrine nasal spray) for the treatment of allergic reactions (type I) including anaphylaxis